Literature DB >> 12239323

A prenylation inhibitor prevents production of infectious hepatitis delta virus particles.

Bruno B Bordier1, Patricia L Marion, Kazuo Ohashi, Mark A Kay, Harry B Greenberg, John L Casey, Jeffrey S Glenn.   

Abstract

Hepatitis delta virus (HDV) causes both acute and chronic liver disease throughout the world. Effective medical therapy is lacking. Previous work has shown that the assembly of HDV virus-like particles (VLPs) could be abolished by BZA-5B, a compound with farnesyltransferase inhibitory activity. Here we show that FTI-277, another farnesyltransferase inhibitor, prevented the production of complete, infectious HDV virions of two different genotypes. Thus, in spite of the added complexity and assembly determinants of infectious HDV virions compared to VLPs, the former are also sensitive to pharmacological prenylation inhibition. Moreover, production of HDV genotype III virions, which is associated with particularly severe clinical disease, was as sensitive to prenylation inhibition as was that of HDV genotype I virions. Farnesyltransferase inhibitors thus represent an attractive potential class of novel antiviral agents for use against HDV, including the genotypes associated with most severe disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239323      PMCID: PMC136538          DOI: 10.1128/jvi.76.20.10465-10472.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

Review 1.  Hepatitis delta virus: molecular biology, pathogenesis and immunology.

Authors:  J L Casey
Journal:  Antivir Ther       Date:  1998

2.  Use of a prenylation inhibitor as a novel antiviral agent.

Authors:  J S Glenn; J C Marsters; H B Greenberg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 3.  Animal models of hepatitis delta virus infection and disease.

Authors:  J L Gerin
Journal:  ILAR J       Date:  2001

4.  The delta agent.

Authors:  M Rizzetto
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

5.  Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.

Authors:  M Rizzetto; M G Canese; S Aricò; O Crivelli; C Trepo; F Bonino; G Verme
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

Review 6.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

Authors:  E K Rowinsky; J J Windle; D D Von Hoff
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

7.  Production and concentration of pseudotyped HIV-1-based gene transfer vectors.

Authors:  J Reiser
Journal:  Gene Ther       Date:  2000-06       Impact factor: 5.250

8.  Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela.

Authors:  Tatsunori Nakano; Craig N Shapiro; Stephan C Hadler; John L Casey; Masashi Mizokami; Etsuro Orito; Betty H Robertson
Journal:  J Gen Virol       Date:  2001-09       Impact factor: 3.891

9.  An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador.

Authors:  S R Manock; P M Kelley; K C Hyams; R Douce; R D Smalligan; D M Watts; T W Sharp; J L Casey; J L Gerin; R Engle; A Alava-Alprecht; C M Martínez; N B Bravo; A G Guevara; K L Russell; W Mendoza; C Vimos
Journal:  Am J Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.345

10.  Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.

Authors:  F Galibert; E Mandart; F Fitoussi; P Tiollais; P Charnay
Journal:  Nature       Date:  1979-10-25       Impact factor: 49.962

View more
  43 in total

1.  By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber/W editing and its own expression.

Authors:  Shuji Sato; Cromwell Cornillez-Ty; David W Lazinski
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

2.  Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen.

Authors:  Brendan O'Malley; David W Lazinski
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

4.  Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.

Authors:  Benjamin Y Winer; Elham Shirvani-Dastgerdi; Yaron Bram; Julie Sellau; Benjamin E Low; Heath Johnson; Tiffany Huang; Gabriela Hrebikova; Brigitte Heller; Yael Sharon; Katja Giersch; Sherif Gerges; Kathleen Seneca; Mihai-Alexandru Pais; Angela S Frankel; Luis Chiriboga; John Cullen; Ronald G Nahass; Marc Lutgehetmann; Jared E Toettcher; Michael V Wiles; Robert E Schwartz; Alexander Ploss
Journal:  Sci Transl Med       Date:  2018-06-27       Impact factor: 17.956

Review 5.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

Review 6.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 7.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

8.  Effects of conserved RNA secondary structures on hepatitis delta virus genotype I RNA editing, replication, and virus production.

Authors:  Geetha C Jayan; John L Casey
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  Therapy of Delta Hepatitis.

Authors:  Cihan Yurdaydin; Ramazan Idilman
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-07       Impact factor: 6.915

Review 10.  Management of hepatitis delta: Need for novel therapeutic options.

Authors:  Zaigham Abbas; Minaam Abbas
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.